Rohto Pharmaceutical ,Ltd. Goodwill

The latest goodwill for RPHCF is $34B as of June 2026. That compares with $33B in the prior-year period — up 2.7% year over year. Investors often review this figure alongside Rohto Pharmaceutical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, RPHCF's goodwill moved from $33B to $34B — a 2.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rohto Pharmaceutical ,Ltd.'s operating scale or balance-sheet position.

A goodwill figure of $34B for RPHCF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RPHCF's goodwill ($34B), review year-over-year change from $33B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.